Erythropoietin acts as a trophic factor in neonatal rat intestine

S E Juul, D J Ledbetter, A E Joyce, C Dame, R D Christensen, Y Zhao, V DeMarco

Abstract

Background—Erythropoietin (Epo) receptors are present on enterocytes of fetal and neonatal small bowel but the role of Epo in the bowel is not known.

Aims—We tested the following hypotheses: (1) enterally dosed Epo is absorbed from the intestines of neonatal rats, (2) Epo acts as a trophic factor in developing small bowel, and (3) the trophic effects of Epo are dependent on the route of administration.

Methods—The dose dependent effects of enterally dosed recombinant human erythropoietin (rEpo 0–1000 U/kg/day) were studied in artificially raised rat pups and compared with dam raised controls and dam raised pups given rEpo in rat milk. After one week, reticulocyte counts, haematocrits, and plasma Epo concentrations were measured, and calibrated morphometric measurements of villi were performed. The effects of route of rEpo administration (enteral v parenteral) on erythropoiesis, bowel growth, and disaccharidase activity were studied in nursing pups treated for one and two weeks.

Results—Serum Epo concentrations ranged from undetectable (<0.6 mU/ml) to 8.4 mU/ml in control and enterally dosed pups (median 1.8 mU/ml), and from 4.9 to 82.3 mU/ml (median 20.4 mU/ml) in parenterally dosed animals. No increase in haematocrit or reticulocyte count was noted in enterally treated pups compared with controls after up to two weeks of treatment. Small bowel length was greater in rEpo treated pups, and a dose dependent increase in villus surface area which was independent of the route of dosing and associated with increased BrdU uptake was found.

Conclusions—rEpo is not enterally absorbed in an intact and functional form from the intestines of neonatal rat pups. Thus enterally dosed rEpo has no erythropoietic effects. However, rEpo acts as a trophic factor in developing rat small bowel whether given enterally or parenterally.

(Keywords: erythropoietin; enterocytes; breast milk; development; neonate; rat)

Erythropoietin (Epo) is present in human milk but its physiological function in the developing intestine is not known. During fetal life, enterocytes are exposed to Epo contained in swallowed amniotic fluid, and in breast fed infants exposure to enteral Epo continues in mother’s milk. We previously reported the presence of Epo receptors (Epo-R) in intestinal villi of developing humans and rats. These Epo receptors appear to be functional, as recombinant Epo (rEpo) increases IEC 6 cell migration, decreases apoptotic death following damage, and has trophic effects on cultured gastric mucosal cells. Thus Epo-R are present on enterocytes, the receptor is functional, and a readily accessible source of its ligand is available to the fetus and breast fed neonate. Possible physiological roles of Epo in the developing gut include: (1) systemic erythropoietic effect following Epo absorption, and (2) local effects.

It is not known if rEpo must be applied locally (enteral dosing) or whether systemically administered rEpo might have effects in the developing bowel. Two studies support the hypothesis that systemic Epo may have important effects in bowel: rats treated with parenteral rEpo prior to a surgical anastomosis showed improved healing, with increased strength of the anastomosis, and secondly, in a retrospective study of infants ≤1250 g who received rEpo for anaemia of prematurity, the incidence of necrotising enterocolitis was lower (4.6% v 10.8%; p<0.05) compared with infants who did not receive rEpo.

Our objectives for this study were to test the following hypotheses: (1) enterally dosed Epo is absorbed from the intestines of neonatal rats in a form that is recognised by ELISA and stimulates erythropoiesis in the animal, (2) Epo acts as a trophic factor in developing small bowel, and (3) the trophic effects of Epo are not dependent on its route of administration.

Materials and methods

Animal instrumentation

All animal experiments were approved by the animal use committee of the University of Florida. Five day old Sprague-Dawley rat pups (11.4 (1.1) g, mean (SD)) (Charles River, Inc, Charleston, South Carolina, USA) were briefly anaesthetised with methoxyflurane until loss of righting reflex was noted. A percutaneous gastrotomy tube (PE-10 tubing) was then inserted. The exteriorised portion of the cannula was secured in place by passing the tubing under a fold of skin on the neck.

Abbreviations used in this paper: BrdU, bromodeoxyuridine; Epo, erythropoietin; Epo-R, erythropoietin receptor; rEpo, recombinant human erythropoietin; RMS, rat milk substitute.
ARTIFICIAL REARING

The cannulae were connected to 12 ml syringes containing chilled (7°C) rat milk substitute (RMS) mounted on a computerised syringe pump apparatus (model 22 syringe pump; Harvard Apparatus, Boston, Massachusetts, USA). Rats were kept individually in 454 g containers containing dust free cob bedding. These were floated in large capacity water baths maintained at 40°C. Rats were fed RMS for 20 minutes every hour. Because of the small diameter of the cannulae and the length of tubing between the refrigerator and the pups (approximately 1 m), the RMS equilibrated to room temperature by the time the RMS entered each pup's stomach. Cannulae were flushed daily with sterile saline to insure patency. Rat pups were weighed and stimulated to micturate and defecate daily.

RAT MILK SUBSTITUTE (RMS)

A formula has been developed which mimics the macro- and micronutrient content of rat’s milk and promotes normal metabolic and developmental events for artificially reared rat pups. RMS contains no Epo, but when rEpo is added, over the concentration range we employ in the infusions, it is stable for a 24 hour period, as judged by ELISA measurements. The volumes of milk infused per day (approximately 230 ml/kg/day on day 5 of life increasing to 370 ml/kg/day on day 12) varied according to the average weight of pups within a treatment group, and was calculated daily.

EXPERIMENTAL CONDITIONS

Experiment 1

Group 1 (n=21) received RMS containing only saline additive. Group 2 (n=11) received RMS containing a daily dose of 200 U/kg rEpo. Group 3 (n=19) received RMS containing a daily dose of 1000 U/kg rEpo. Groups 4 and 5 were sham operated (anaesthetised, and PE-50 inserted into stomach but no perforation) and returned to their dams, treated with either intraperitoneal saline injections (group 4, n=20) or intraperitoneal rEpo 200 IU/day (group 5, n=18). After seven experimental days, rats were given an overdose of pentobarbital intraperitoneally. Blood was withdrawn from the right ventricle into a heparinised syringe. After withdrawing an aliquot for determination of haematocrit and reticulocyte count, plasma was separated and stored for Epo ELISA. The animals were perfusion fixed by inserting a needle into the left ventricle, cutting the right auricle, and flushing with phosphate buffered saline until clear, followed by a 4% paraformaldehyde infusion. The entire small bowel was removed, weighed, and the length from stomach to ileoceleal junction measured. Each animal had a 4 cm segment from the proximal duodenum, mid jejunum, and terminal ileum paraffin embedded for histological evaluation.

Epo ASSAY

Epo concentrations in plasma and milk were assayed using the Quantikine IVD human Epo Immunoassay ELISA (R&D Systems, Minneapolis, Minnesota, USA). Blood samples were drawn by cardiac puncture for measurement of haematocrit and reticulocyte counts, and plasma was separated and stored for Epo ELISA. The entire small bowel was removed, weighed, and the length from stomach to ileoceleal junction measured. Each animal had a 4 cm segment from the proximal duodenum, mid jejunum, and terminal ileum paraffin embedded for histological evaluation.

MANUAL EXPRESSION OF RAT MILK

To determine Epo concentrations in milk from dams treated with rEpo, measurements were made at timed intervals following single or multiple injections of 200 U rEpo intraperitoneally. Rat dams were lightly anaesthetised with pentobarbital (0.1–0.2 mg/kg intraperitoneally) and then given oxytocin (4 IU/kg intraperitoneally) to stimulate milk let down. Milk was then manually expressed. Between 1 and 1.5 ml milk were obtained per milking.

Experiment 2

To determine if the effects of Epo in bowel milk were route dependent (enteral vs parenteral), a second model was employed: for each experiment, Sprague-Dawley rats from three litters were delivered and mixed, such that the average weight of all pups was the same in each group. On day 5 of life, three groups were formed (n=10–12/group/experiment). The group 1 dam received a daily injection of sterile saline 200 µl intraperitoneally (controls). The group 2 dam received a daily intraperitoneal injection of 200 U rEpo; thus pups in this group were exposed to rEpo excreted into the dam’s milk. In the third group, each pup received a daily dose of 200 U/kg/day subcutaneous rEpo. Pups continued to suckle as usual. Experiments were carried out for either seven or 14 days. At the time of sacrifice, blood was drawn by cardiac puncture for measurement of haematocrit and reticulocyte counts, and plasma was separated and stored for Epo ELISA. The entire small bowel was removed, weighed, and the length from stomach to ileoceleal junction measured. Each animal had a 4 cm segment from the proximal duodenum, mid jejunum, and terminal ileum paraffin embedded for histological evaluation.

MORPHOMETRIC MEASUREMENTS

Ten digitised images each from the duodenum, jejunum, and ileum were evaluated from each animal using the calibrated Analytical Imaging System (Imaging Research Inc, St Catharines, Ontario, Canada). Images from the attached light microscope were digitised at 25X magnification. An investigator blinded to the treatment group measured the number of villi/mm bowel wall, villus length, diameter, area, and crypt depth for each digitised image. Images were digitised only if they had a minimum of six measurable intact villi in the field.

DISACCHARIDASE ACTIVITY

A subset of animals were not perfusion fixed (n=21). After measurements of their bowel were made, weighed segments of duodenum,
jejunum, and ileum were homogenised in 0.010 M NaH₂PO₄/Na₂HPO₄, pH 6.0, containing 0.002% Triton X-100 for later evaluation of disaccharidase activity. The following maltose, sucrose, and lactose solutions were used as substrate for maltase, sucrase, and lactase activity, respectively: 0.0156 M maltose in 0.05 M NaH₂PO₄/Na₂HPO₄, pH 6.0, 0.04 M sucrose in 0.05 M NaH₂PO₄/Na₂HPO₄, pH 6.0, and 0.188 M sucrose in 0.05 M NaH₂PO₄/Na₂HPO₄, pH 6.0. A glucose standard curve ranging from 0 to 200 µM was prepared. After incubating an aliquot of test homogenate with each solution for 30 minutes at 37°C, cold Trinder reagent (Sigma) was added to all tubes, including the standard curve samples. After incubation at 37°C for 30 minutes, absorbance at 505 nm was measured.

DETERMINATION OF CELL TURNOVER IN VILLI
A subset of animals (n=24) received timed injections of bromodeoxyuridine (BrDU 50 mg/kg) intraperitoneally two hours prior to death, and were perfusion fixed with 4% paraformaldehyde infusion. Segments (2 cm) were cut from the proximal duodenum, mid jejunum, and distal ileum. Tissue was fixed overnight in 4% paraformaldehyde, changed to 80% alcohol, and paraffin embedded. Sections (4 µm) were placed on poly-L-lysine coated slides and dried for two hours at 60°C. After deparaffinisation in two xylene washes, and rehydration through a graded series of alcohols, finishing with water, tissues were quenched in 3% H₂O₂, and permeabilised with trypsin. Biotinylated mouse anti-BrDU was then applied, with streptavidin-peroxidase, and diaminobenzidine used for visualisation, as directed by the BrdU staining kit (HC524) from Oncogene (Boston, Massachusetts, USA). Haematoxylin was used as a counterstain. To determine the percentage of crypt cells which were BrDU positive, three fields per bowel segment were counted at 400× for each specimen. Only fields in which at least one positive crypt cell was present were chosen. All crypt cells in the field were counted and designated either positive or negative.

STATISTICAL ANALYSIS
The Student’s t test with Bonferroni correction for multiple comparisons was used to compare morphometric parameters. Variables measured repeatedly within a subject were averaged for the correlation analysis. All tests were two sided and tested at an alpha value of 0.05. Spearman rank correlations were used to examine linear and non-linear associations between Epo concentrations in milk and serum. Values are reported as mean (SEM) unless otherwise stated.

Results
ARTIFICIALLY RAISED PUPS AND NURSING CONTROLS
After one week of therapy, serum Epo concentrations were not different between the three groups of artificially raised pups, or nursing control pups (fig 1A). Similarly, reticulocyte counts and haematocrits were not different between groups (fig 1B). Weight gain in the artificially reared pups was consistently lower than in the nursing control pups. However, there were no differences in weight gain between the three artificially reared groups.

Epo concentrations in RMS were measured before and after refrigeration for 24 hours. Epo concentrations were undetectable, 371 (18) mU/ml, and 4338 (425) mU/ml in control, low dose, and high dose RMS, respectively. No differences were noted before and after refrigeration for 24 hours. Serum and milk Epo concentrations were measured in dams from groups 4 and 5 after seven days of treatment. Haematocrits of the rEpo treated dams were high, ranging from 72% and 76% versus 37% to 44% in control dams. Epo concentrations in rat milk were dependent on the proximity of the testing to rEpo dosing. Mean milk Epo concentration after intraperitoneal injection was 68.9 (24.9)
mU/ml (range 1.2–256); mean serum Epo concentration was 746.9 (252.5) mU/ml (range 16.5–2200). The correlation coefficient for milk versus serum Epo was $r^2=0.522$. Milk Epo concentrations after a single injection, and 24 hours after seven days of daily injections (steady state) are shown in fig 2.

Mean bowel length in the high dose group was 42.7 (3.1) cm while in control pups it was 40.4 (0.6) cm (p=0.09). Pups which had suckled from the rEpo treated dam had an average bowel length of 52.2 (0.8) cm while control pups had an average bowel length of 47.7 (1.3) cm (p<0.02). There were no significant differences in body weight between the rEpo and control pups.

We next evaluated the bowel of rEpo treated rats compared with controls by light microscopy. Enterally dosed rEpo increased villus surface area of the proximal jejunum in a dose dependent manner. Table 1 shows computer calibrated measurements of villi for the artificially reared pups and nursing pups. Enteral rEpo had a trophic effect on small bowel villi (proximal jejunum) whether given in RMS or in mothers’ milk, increasing villus surface area, length, and villus density (number of villi/mm of bowel wall). We observed no effect of rEpo on villus diameter or villus length to crypt depth ratio.

ENTERAL VERSUS PARENTERAL rEpo EFFECTS

Epo concentrations and haematocrit values for the three experimental groups treated for one and two weeks are shown in fig 3. Trough Epo concentrations (24 (1) hours after the last injection) are shown for animals treated for one week while peak Epo concentrations (5 (1) hours after the last injection) are shown for animals treated for two weeks. Epo concentrations and haematocrit values in animals who received enteral rEpo were not different than controls, regardless of duration of therapy. In pups who received subcutaneous rEpo, both Epo concentrations and haematocrit values were higher than controls.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Mean villus surface area, length, diameter and crypt depth</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Villus surface area (µm$^2$)</td>
</tr>
<tr>
<td>AR control, n=55</td>
<td>16 120 (585)</td>
</tr>
<tr>
<td>AR low dose rEpo (n=55)</td>
<td>17 950 (725)</td>
</tr>
<tr>
<td>AR high dose rEpo (n=39)</td>
<td>21 250 (722)††</td>
</tr>
<tr>
<td>NP control (n=38)</td>
<td>14 800 (1028)</td>
</tr>
<tr>
<td>NP rEpo treated dam (n=39)</td>
<td>17 400 (716)*</td>
</tr>
</tbody>
</table>

AR control, artificially raised pups; AR low dose rEpo, artificially raised pups, 200 U/kg/day enteral human recombinant erythropoietin (rEpo); AR high dose rEpo, artificially raised pups, 1000 U/kg/day enteral rEpo; NP control, nursing pups control; NP rEpo treated dam, nursing pups, dam treated with 200 U rEpo/day intraperitoneally.

*p<0.05, ††p<0.01 compared with pups nursing from rEpo treated dam; †p<0.05, †††p<0.001 compared with artificially raised control pups.

Values are mean (SEM) or number.
To determine if rEpo acted as a maturation factor, lactase, maltase, and sucrase activity was evaluated in weighed bowel segments from each group (n=6 per group). As expected in rat pups of this age, little to no sucrase activity was present, and only minimal maltase activity, which was consistently highest in the distal jejunum/ileum, and when measured as a function of grams of bowel weight, did not vary as a result of rEpo treatment.

Mean bowel length after one week of therapy was 50.9 (0.7) cm, 52.3 (0.8) cm, and 51.4 (0.6) cm for control, enteral, and parenteral rEpo groups, respectively. When corrected for body size (bowel length (cm) divided by weight (g)), mean bowel length/body weight was greater in the enteral rEpo group compared with controls (p<0.005) but not in the parenterally treated group (p=0.13) (1.72 (0.04), 1.91 (0.05), and 1.81 (0.04) cm/g, respectively). After two weeks of therapy, both rEpo treated groups had increased bowel length/g body weight compared with controls although the increase was most pronounced in the enterally treated group (1.68 (0.07) controls, 2.12 (0.03) enteral rEpo, and 1.87 (0.04) parenteral rEpo; p<0.0001 and 0.05, respectively).

In the duodenum, villi from enterally treated pups were not different from controls but villi from pups receiving parenteral rEpo had greater surface area (p<0.0001, 95% confidence interval (CI) 171–287), length (p<0.0001, 95% CI 88–144), and crypt depth (p<0.0001, 95% CI 6–20). In the jejunum, villus surface area was greater in both rEpo treated groups (p<0.05, CI 8–12 for enterally treated pups; p<0.0001, CI 111–239 for parenterally treated pups). Villus length was greater in both rEpo treated groups compared with controls (p<0.0001, CI 33–121 for enterally treated pups; p<0.0001, CI 55–118 for parenterally treated pups). Villus diameter was greater in enterally treated pups (p<0.01) but not in parenterally treated pups. The greatest differences were noted in the ileum with increased villus surface area, length, and crypt depth in both rEpo treated groups. Findings are summarised in fig 4.

We postulated that one mechanism by which villus length might increase is by increased crypt cell division. Indeed, BrdU incorporation was significantly greater in the crypts and villi of animals receiving either enteral or parenteral rEpo compared with controls. These differences were more pronounced in distal than in proximal small bowel, with the most profound differences noted in the ileum. In the ileum, BrdU incorporation was noted in the villus tips as well as in the crypts of animals receiving rEpo, as can be seen in fig 5. Figure 6 shows the percentage of crypt cells which were BrdU positive in the duodenum, jejunum, and ileum from each treatment group.

Discussion

Growth factors are present in amniotic fluid and milk ingested during fetal and postnatal development. Some of these have been shown to have important trophic effects in the developing bowel. Other factors, such as Epo, are known to be present in these fluids but their roles have not yet been defined. The present studies have focused on the biological functions of Epo-R within the developing intestine.

The hypothesis that Epo can be enterally absorbed is supported by work from Carmichael and colleagues showing an increase in erythropoiesis in nursing rat pups following maternal phlebotomy, suggesting that Epo may be transmitted through mother’s milk in rodents, although Epo concentrations in milk or pups were not measured. A pilot study addressing this issue in humans was performed in six premature infants. Each infant was given an oral dose of Epo 1000 U/kg/day for 10 days with serum Epo concentrations measured at timed intervals following the oral dose. A small but statistically significant increase in circulating Epo concentrations was observed two hours following the dose but at
no other time points. No increase in haematocrit or reticulocyte counts were observed. Unfortunately, rEpo was given in a non-protein containing buffered solution which may have significantly decreased the stability of the protein. A recent prospective study of 12 infants randomised to receive enteric rEpo (600 U/kg/week given three times a week) or placebo showed that enteric rEpo might result in increased erythropoiesis, although there was no difference in red blood cell transfusions required.

In this study, we found no difference between serum Epo concentrations of artificially reared rat pups receiving one week of enteral rEpo in doses of 200 U/kg/day, 1000 U/kg/day, or no exogenous enteral rEpo. Similarly, when pups were suckled, and received rEpo via rat milk for one or two weeks, no difference in haematocrit was noted compared with controls, although the haematocrit in a third group of pups treated daily with subcutaneous rEpo increased significantly during the experimental period, as did the haematocrit of the dams receiving rEpo. Thus it is unlikely that a significant role of Epo-R in rat bowel is absorption of enteric Epo, although we cannot rule out the possibility that small quantities of enterally dosed rEpo were absorbed. It is possible that the use of human rEpo in the rat model may have decreased enteric absorption compared with endogenous rat Epo, as rat and human Epo are only 80–82% homologous. However, human and rat Epo show biological and immunological cross reactivity (as demonstrated by the increased haematocrit values in parenterally treated pups and rEpo treated dams), and hence this is an unlikely explanation for the low absorption of rEpo.

Our second hypothesis was that enterally dosed rEpo would (versus would not) have trophic effects in the small bowel. We clearly showed that rEpo, when given enterally for at least one week in either RMS or rat milk, significantly increases the length of the small bowel and also increases the absorptive surface.

Figure 5 Bromodeoxyuridine (BrdU) incorporation in neonatal rat small bowel. All images were taken at an original magnification of 400×. (A, B) Duodenum and ileum from control animals; (C, D) duodenum and ileum from animals treated with recombinant human erythropoietin intraperitoneally (PO rEpo); and (E, F) duodenum and ileum from subcutaneous rEpo (SC rEpo) treated animals. Brown staining shows BrdU positive cells.
area of microvilli, primarily by an increase in villus length. rEpo did not affect the specific activity of disaccharidases, as no differences in lactase, maltase, or sucrase activities were detected in any bowel segment between treatment groups. However, as the length of the small bowel increased with rEpo treatment, but the specific activity of the disaccharidase stayed the same, we can extrapolate that the total activity increased. This was most significant for lactase activity, followed by maltase activity, as minimal to no sucrase was present in any treatment group.

Lastly, we hypothesized that the effects of rEpo in bowel would (versus would not) be route dependent. We found that rEpo, given enterally or parenterally, acts as a trophic factor in small bowel. There are however some route dependent differences: enterally dosed rEpo had a greater effect on small bowel length (normalised to body weight) than parenteral rEpo while both enteral and parenteral rEpo were associated with increased villus surface area. The effects of rEpo on villus length and surface area were most pronounced in the ileum. The precise mechanism by which this increase occurs is not clear but it appears to involve an increase in cell turnover, as demonstrated by our BrdU incorporation studies. The unusual finding of BrdU positive cells in the villi may reflect a combination of increased cell turnover and an increase in cell migration associated with rEpo administration.

Epo-R are present on a variety of non-haematopoietic cell types, including enterocytes, endothelial cells, smooth muscle cells, and neurones, cell types which are present in the developing bowel. It is possible that rEpo acts as a trophic factor on one or more of these cell types during growth and development. Enteral rEpo is clearly not an essential requirement for postnatal bowel development, human neonates are often fed non-Epo containing infant formulas and do well. Possible explanations include that circulating Epo is sufficient for normal bowel development or that Epo is not an essential growth factor for growth development. Unfortunately, the homozygous null mutation or “knockout” mouse models which are either Epo or Epo-R deficient do not survive gestation, dying at embryonic day 13.5 (approximately 65% of gestation). It has therefore not been possible to use these models to evaluate the effects of Epo on the growth and development of the bowel.

In summary, we have shown that enterally dosed rEpo is not absorbed in amounts sufficient to promote increased erythropoiesis but that it is associated with trophic effects in the developing neonatal rat intestine, increasing small bowel length and villus surface area. Parenterally dosed rEpo has the expected erythropoietic effects, as well as trophic effects in the small bowel. The potential clinical usefulness of these observations are apparent for such conditions as short bowel syndrome (resulting from necrotising enterocolitis or other bowel catastrophes), in which increasing the small bowel surface area would be of clinical benefit. The relevance of these findings to adults has not been studied and is unknown. Further investigation must be done to determine the clinical applicability of these important findings.

Supported by CAP award RR-00082 from the National Institutes of Health, and by the Children’s Miracle Network.

Conflict of interest: S Juul is a consultant for Johnson and Johnson.


